GT Biopharma, Inc. Annual Operating Income (Loss) in USD from 2010 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
GT Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2024.
  • GT Biopharma, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$3.76M, a 18.8% decline year-over-year.
  • GT Biopharma, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$14.4M, a 5.8% decline year-over-year.
  • GT Biopharma, Inc. annual Operating Income (Loss) for 2024 was -$14.4M, a 5.8% decline from 2023.
  • GT Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$13.6M, a 36.1% increase from 2022.
  • GT Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$21.3M, a 63% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.